Videlis Nduba, MD, PhD

Centre Director, Centre for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI)

Dr. Videlis Nduba, MD, PhD, is a centre director at the Centre for Respiratory Diseases Research, Kenya Medical Research Institute, in Nairobi, Kenya. As a medical officer from Kenya and epidemiologist trained at the school of public health at the University of Washington, Seattle, he started his career working in HIV and eventually transitioned to respiratory diseases. He has 18 years of clinical trials experience and has conducted multiple trials in tuberculosis vaccines, TB drug trials, sickle cell disease, and malaria drug trials.

Publications

  1. Bello-Manga, H, Abdullahi, SU, Hassab, H, Brown, B, Nduba, V, Githanga, J et al.. HOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities. Am J Hematol. 2026; :. doi: 10.1002/ajh.70457. PubMed PMID:42665434 .
  2. Wattiau, P, Omar, SV, Joseph, L, Demoitié, MA, Gilbert, M, Ayles, HM et al.. Genetic characterization of M. tuberculosis isolates from participants in a Phase 2b randomized trial evaluating the M72/AS01E tuberculosis candidate vaccine. J Infect Dis. 2026; :. doi: 10.1093/infdis/jiag428. PubMed PMID:42663178 .
  3. Musau, S, Odera, S, Musyoki, VM, Lamont, EI, Onyango, N, Morrison, B et al.. Genomic characterization of drug-resistant Mycobacterium tuberculosis complex in western Kenya reveals predominance of isoniazid resistance and discordance with routine susceptibility testing. Front Tuberc. 2026;4 :1855780. doi: 10.3389/ftubr.2026.1855780. PubMed PMID:42638759 PubMed Central PMC13491443.
  4. Nduba, V, Mathebula, M, Nankabirwa, V, Dempster, M, Mhimbira, F, Sabi, I et al.. Comparison of VPM1002 with BCG in the prevention of tuberculosis in newborn infants: a multicentre, double-blind, randomised, phase 3, non-inferiority trial. Lancet Infect Dis. 2026; :. doi: 10.1016/S1473-3099(26)00374-9. PubMed PMID:42612668 .
  5. Sunshine, J, Shaffer, M, Han, LL, Gaikwad, D, Houana, AA, Gler, MT et al.. Associations Between QuantiFERON-TB Gold Plus IFNγ Concentrations and Progression to Symptomatic Tuberculosis in Global High-Burden TB Settings. Open Forum Infect Dis. 2026;13 (7):ofag437. doi: 10.1093/ofid/ofag437. PubMed PMID:42500121 PubMed Central PMC13397382.
Search PubMed